admin A memorandum of understanding was signed by Sandoz, a global leader in generic and biosimilar medicines today, to construct a new biologics production plant in Lendava, Slovenia. The Sandoz investment is anticipated to be at least USD 400 million, subsidizing the company’s mission to power the future growth of its global biosimilars portfolio.
Dr Robert Golob, Prime Minister of the Republic of Slovenia, at the signing ceremony stated, “I am particularly pleased that this is an investment by a long-term strategic investor, a socially responsible and sustainable company, which is already one of the largest and most respected employers in Slovenia. With such investments, we are well on our way to a highly productive, competitive and green economy.”
Sandoz CEO Richard Saynor said: “Biosimilar medicines increase access to cutting-edge biologic therapies for the patients who need them most. At Sandoz, we are determined to continue leading the way on driving access to these critical medicines. This investment underscores our ambition to be the sustainable global leader in biosimilars, a segment projected to grow double-digit annually over the next decade.”
Antibiotics is the second largest Sandoz business after Biopharmaceuticals, and both have their roots in the company’s unique 75-year history of developing fermentation-based production technologies. Sandoz newly announced an additional EUR 50 million investment to expand its European-based antibiotics production network, bringing the total new investment commitment to the network in the past few years to EUR 250 million.
Sandoz is a pioneer in biosimilars and the leading global producer of generic antibiotics. This company is determined to grow in leadership in these two critical and developing segments of the off-patent medicines market.
Magazine
